Skip to content

Dianthus Therapeutics

US · DNTH #2155 by market cap Listed 1970
84.55 -0.28 -0.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Price chart

Pre-market 83.77 -1.25%
After-hours 84.08 -0.56%
115.9672.0984.552026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on DNTH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +43.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 16.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -8,739.3% Better than 1%
Net margin -7,973.3% Better than 1%
Return on equity -38.4% Better than 11%
Return on invested capital -42.1% Better than 7%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -23.9% Better than 25%
6-month return -2.2% Better than 52%
12-month return (ex latest month) 85.2% Better than 93%
Distance below 52-week high 28.3% Better than 45%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.3x Better than 96%
Debt to assets 0.3% Better than 97%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 59.2% Better than 71%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.91%
1M +7.37%
3M -22.79%
6M -4.70%
YTD +105.17%
1Y +109.33%
3Y +627.62%
5Y -21.01%

Key statistics

Price & volume

Prev close
84.83
Open
83.62
Day range
82.53 - 85.67
Avg price
84.25
Volume
799.66K
Turnover
67.37M
Amplitude
3.70%
52-week range
35.84 - 117.88

Valuation

P/E
-20.13
P/E (TTM)
-20.72
P/B
3.84
EPS
-4.20
Net profit
-236.51M
Net assets
1.24B

Share structure

Market cap
4.76B
Float cap
4.75B
Shares out
56.31M
Float shares
56.23M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 59% of range
35.84 117.88

28.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+8.41M net over the window

Short interest

Shares short
9.28M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Dianthus Therapeutics (DNTH)?

Dianthus Therapeutics last traded at 84.55. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Dianthus Therapeutics's market cap?

About 4.76B.

What is the P/E ratio of Dianthus Therapeutics?

The trailing twelve-month P/E is -20.72. The Valuation tab shows it against the stock's own five-year range.

Does Dianthus Therapeutics pay a dividend?

Dianthus Therapeutics does not currently pay a regular dividend.

Is Dianthus Therapeutics a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 134.63, which implies 59.2% upside from the current price. This is not investment advice.

What is Dianthus Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Dianthus Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.

Dianthus Therapeutics discussion 0 comments

Add a comment